Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

Launched by LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER IN NEW ORLEANS · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how often patients should receive botulinum toxin (commonly known as Botox) injections to treat overactive bladder (OAB). The main goal is to find out if allowing patients to choose their own follow-up times, based on when their symptoms return, can improve the effectiveness of the treatment compared to the usual 6-month schedule. Researchers want to see if this approach leads to better control of symptoms and higher satisfaction for patients.

To participate in this trial, women aged 65 to 74 who have been diagnosed with conditions like overactive bladder, urinary urgency, or urge urinary incontinence could be eligible. Participants will receive the standard Botox injection into their bladder and will then be assigned to follow up either every 6 months or whenever they feel their symptoms come back. It’s important to note that the trial is not yet recruiting participants. This study could help improve the way we manage OAB by tailoring treatment schedules to individual needs.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of overactive bladder, detrusor overactivity, urinary urgency, urinary frequency, nocturnal polyuria, or urge urinary incontinence
• • pursuing treatment with intravesical botulinum toxin injections
• Exclusion Criteria:
• • - non-OAB diagnosis such as pelvic pain or interstitial cystitis